Worldwide Clinical Trials | Oncology

Developing Cutting-Edge Treatments for Ovarian Cancer

Ovarian cancer is a core area of expertise for Worldwide Clinical Trials. Over the last five years, we have managed complex first-in-human to large Phase III ovarian cancer trials across North America, Europe, Asia-Pacific, Latin America, and the Middle East & North Africa, including experience in rare ovarian cancer subtypes (e.g. LGSOC).

Referral pathways and a highly competitive landscape make clinical trial enrollment in ovarian cancer studies challenging. Partnering with a CRO that understands the operational nuances of oncology studies and has strong site and cooperative group relationships is critical to accelerating enrollment and trial success.

Robust pipeline of ovarian cancer trials

Global Footprint

- Programs across North America, Europe, Asia-Pacific, Latin America, and the Middle East and North Africa

Study Experience

- Phase I to Phase III trials
- 40+ trials enrolling 4,700+ patients

Site Experience

- 320+ investigative sites in 25 countries

FDA designations

- Fast track
- Accelerated approval

Next-generation drug modalities

- Antibody-drug conjugates (ADCs)
- Multi/bi-specific antibodies
- Cell therapies/CAR T
- Inhibitors (checkpoint, kinase, PARP, and small molecule)
- Peptide drug conjugates
- Vaccines

We understand ovarian cancer trials

- Complex endpoints: RECIST interpretation of peritoneal studding, previously treated tumors, ascites and pleural effusions
- CA-125 criteria for screening, stratification and response evaluation
- I/E criteria: complex prior treatment histories, wash-out windows
- Cooperative group involvement is common: Gynecologic Oncology Group (GOG) in the US and European Network for Gynaecological Trials (ENGOT) in EU
- Competitive clinical trial landscape
- Enrollment challenges and complex trial logistics

40+
Ovarian Cancer Studies

4,700+
Patients Enrolled

320+
Investigative Sites

Global Footprint
NA, EU, APAC, LATAM, MENA

What Sets Us Apart

Biotech Mindset Delivered Worldwide

We are purpose built around a biotech mindset that shapes both our partnership philosophy and delivery model, bringing the agility, responsiveness, and focus needed to meet critical oncology development milestones.

Oncology Expertise and Team Continuity

Oncology expertise is embedded across all functions, ensuring studies are led by professionals who understand the complexities of oncology science and trial execution. With an average of 11+ years of oncology experience across key roles and an industry-leading 90%+ retention rate in the oncology business unit, you can expect a seasoned, specialized team supporting your study end to end.

Flexible solutions & best-in-class technologies

Data-centric approach with visual analytics & clinical science

Site relationships with rapid startup

Global footprint: 4,000+ across NA, EU, LATAM, MENA & APAC

Active Next-Gen Oncology Experience

Operating both locally and globally across Phases I through III in a range of solid tumor and hematologic indications, we understand the nuances of complex study designs, novel endpoints, and cutting-edge modalities.

Phase



Early Phase · Late Phase · Observational/LTFU

Indication



Solid · Heme

Drug Class



Immuno-Oncology · Other · Targeted Therapy

Worldwide Clinical Trials

Oncology at Worldwide

Worldwide features a dedicated oncology business unit within our full-service global contract research organization. We partner with biopharmaceutical sponsors to deliver expert-led, globally scalable oncology trials across every phase of development. We help sponsors move fast with confidence and scale without disruption.

Contact us to learn how we can support your oncology program from FIH through registration.